| Literature DB >> 23935400 |
Julie Dupouy1, Guillaume Moulis, Marie Tubery, Marie Ecoiffier, Agnès Sommet, Jean-Christophe Poutrain, Philippe Arlet, Maryse Lapeyre-Mestre.
Abstract
BACKGROUND: Adverse events result in longer hospital stays and increase costs and mortality. We aimed to assess incidence of adverse events occurring during hospitalization in a post-emergency unit and to describe their characteristics.Entities:
Keywords: Adverse event; hospitalization; inpatients; internal Medicine; pharmacovigilance
Mesh:
Year: 2013 PMID: 23935400 PMCID: PMC3739022 DOI: 10.7150/ijms.6640
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Figure 1Flowchart illustrating the patient selection process in the post-emergency unit of Toulouse university hospital. PMSI Programme de Médicalisation des Systèmes d'Information Médicale, medical information systems program database.
Drugs related to adverse events according to anatomical therapeutic chemical class.
| Drug classes | n | % |
|---|---|---|
| N02 Analgesics | 13 | 16.7 |
| N03 Antiepileptics | 4 | 5.1 |
| N05 Psycholeptics | 17 | 21.8 |
| N06 Psychoanaleptics | 3 | 3.9 |
| J01 Antibacterials for systemic use | 16 | 20.5 |
| J05 Antivirals for systemic use | 1 | 1.3 |
| C01 Cardiac therapy | 3 | 3.9 |
| C03 Diuretics | 2 | 2.6 |
| C07 Beta blocking agents | 2 | 2.6 |
| C09 Agents acting on the renin-angiotensin system | 1 | 1.3 |
| B01 Antithrombotic agents | 5 | 6.4 |
| B05 Blood substitutes and perfusion solutions | 1 | 1.3 |
| H02 Corticosteroids for systemic use | 5 | 6.4 |
| M01Antiinflammatory and antirheumatic products | 1 | 1.3 |
| M03 Muscle relaxants | 1 | 1.3 |
| A10 Drugs used in diabetes | 1 | 1.3 |
| P01 Antiprotozoals | 1 | 1.3 |
| R03 Drugs for obstructive airway diseases | 1 | 1.3 |
Description of drug-related events and drugs involved.
| Drug-related events | Number of occurrences | Drugs (number of times drug was involved) |
|---|---|---|
| 17 | Psycholeptics (13), Analgesics (5), Antiepileptics (2), Psychoanaleptics (2), Antibacterials (2), Antivirals (1), Corticosteroids (1), Beta blocking agents (1) | |
| 7 | Analgesics (5), Antiepileptics (1), Antibacterials (1), Muscle relaxants (1) | |
| 6 | Corticosteroids (4), Diuretics (1), Beta Blocking agents (1), Blood substitutes and perfusion solution (1), Drugs used in diabetes (1), Antibacterials (1), Drugs for obstructive airway diseases (1) | |
| 6 | Antibacterials (5), Analgesics (2), Antiprotozoals (1) | |
| 4 | Antithrombotic agents (5), Antibacterials (1), Analgesics (1) | |
| 3 | Antibacterials (3) | |
| 3 | Antibacterials (3), Psychoanaleptics (1) | |
| 2 | Cardiac therapy (3) | |
| 2 | Psycholeptics (4), Antiepileptics (1), Diuretics (1), Agents acting on the renin-angiotensin system (1) | |
| 1 | Antiinflammatory and rheumatic products (1) |
Characteristics of cases and controls, n=170.
| Cases | Controls | p value | |
|---|---|---|---|
| 28 (53.8) | 67 (56.8) | 0.7 | |
| 82 [72-86] | 82.5 [75-88] | 0.6 | |
| 25 (48.1) | 66 (55.9) | 0.4 | |
| 10 (19.2) | 32 (27.1) | 0.4 | |
| 6 [3-8] | 7 [4-9] | 0.1 | |
| 1 [0-3] | 2 [1-3] | 0.02 | |
| 6.5 [4-8] | 5 [3-6] | 0.007 |
Q1, first quartile; Q3 third quartile
Charlson comorbid conditions (with weights) present at admission for all patients included in the conditional logistic regression.
| Charlson comorbid conditions | Weight | No (%) of patients | No (%) of cases | No (%) of controls |
|---|---|---|---|---|
| Myocardial infarction | 1 | 26 (15.3) | 8 (15.4) | 18 (15.3) |
| Congestive cardiac failure | 1 | 39 (22.9) | 11 (21.2) | 28 (23.7) |
| Peripheral vascular disease | 1 | 27 (15.9) | 4 (7.7) | 23 (19.5) |
| Cerebrovascular disease | 1 | 20 (11.8) | 9 (17.3) | 11 (9.3) |
| Dementia | 1 | 38 (22.4) | 10 (19.2) | 28 (23.7) |
| Chronic pulmonary disease | 1 | 25 (14.7) | 7 (13.5) | 18 (15.3) |
| Rheumatological disease | 1 | 8 (4.7) | 0 (0.0) | 8 (6.8) |
| Peptic ulcer disease | 1 | 8 (4.7) | 1 (1.9) | 7 (5.9) |
| Mild liver disease | 1 | 5 (2.9) | 0 (0.0) | 5 (4.2) |
| Diabetes (mild to moderate) | 1 | 30 (17.7) | 6 (11.5) | 24 (20.3) |
| Diabetes with complications | 2 | 7 (4.1) | 3 (5.8) | 4 (3.4) |
| Hemiplegia or paraplegia | 2 | 3 (1.8) | 1 (1.9) | 2 (1.7) |
| Renal disease | 2 | 14 (8.2) | 1 (1.9) | 13 (11.0) |
| Any malignancy, including lymphoma/leukemia | 2 | 32 (18.8) | 9 (17.3) | 23 (19.5) |
| Moderate or severe liver disease | 3 | 2 (1.2) | 1 (0.9) | 1 (1.9) |
| Metastatic solid tumor | 6 | 4 (2.4) | 0 (0.0) | 4 (3.4) |
| Acquired immunodeficiency syndrome AIDS | 6 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Factors associated with occurrence of intra hospital adverse events *.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| OR [95% CI] | p value | OR [95% CI] | p value | |
| 0.97 [0.48-1.95] | 0.9 | - | - | |
| 1.14 [0.56-2.29] | 0.7 | - | - | |
| 0.69 [0.34-1.39] | 0.3 | - | - | |
| 0.66 [0.29-1.50] | 0.3 | - | - | |
| 0.62 [0.31-1.24] | 0.2 | - | - | |
| 0.42 [0.22-0.83] | 0.01 | 0.41 [0.21-0.80] | 0.009 | |
OR, odds ratio; 95% CI, confidence interval at 95%.
*Variables initially included in the model were age, sex, number of drugs, Charlson score, dependency, hospitalization in the previous year.